Harbour Investments’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Harbour Investments’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-9	Closed	-$918	–	3136
2023 Q2	$918	Hold	9	–	–	﹤0.01%	2709
2023 Q1	$818	Hold	9	–	–	﹤0.01%	2720
2022 Q4	$342	Hold	9	–	–	﹤0.01%	2831
2022 Q3	$0	Hold	9	–	–	﹤0.01%	2876
2022 Q2	$0	Buy	+9	New	+$268	﹤0.01%	2876
2021 Q4	$0	Hold	9	–	–	﹤0.01%	3885
2021 Q3	$1K	Hold	9	–	–	﹤0.01%	3657
2021 Q2	$1K	Buy	+9	New	+$1.02K	﹤0.01%	3698

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Harbour Investments's RETA Position: Q3 2023 in Review

Harbour Investments sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 9 shares — an estimated $918 sold.

Harbour Investments first reported a position in RETA in Q2 2021 and held it in 8 quarters. The position peaked at $1K in Q3 2021. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Harbour Investments reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Harbour Investments sold 9 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $918.
Harbour Investments first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2021 and held it in 8 quarters.
Harbour Investments's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $1K in Q3 2021.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Harbour Investments's 13F filing for Q3 2023, filed 15 Nov 2023.